Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Omeprazole | Research

Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study

Authors: Mengmeng Wang, Lingjian Zhang, Min Jia, Junyan Wang, Zhiwen Shen, Shuyue Wang, Xinghui Zhang, Jing Xu, Zheng Zheng, Xuanrui Lv, Xiaoyu Zong, Hui Li, Jin Zhou, Tong Meng, Mingzhu Chen, Bin Zhao, Jian Gong

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Aim

The objective of this study was to evaluate the reported associations between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and a variety of proton pump inhibitors (PPI) through analysis of the reports extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS).

Methods

FAERS reports from January 2004 to March 2020 were used to conduct disproportionality and Bayesian analyses. The definition of SIADH relied on the preferred terms provided by the Medical Dictionary for Regulatory Activities. The time to onset, mortality, and hospitalization rates of PPI-related SIADH were also investigated.

Results

The study identified a total of 273 reports of PPI-associated SIADH, which appeared to influence more elderly than middle-aged patients (71.1% vs. 12.5%). Women were more affected than men (48.7% vs. 41.8%). Rabeprazole had a stronger SIADH association than other PPIs based on the highest reporting odds ratio (reporting odds ratio = 13.3, 95% confidence interval (CI) = 7.2, 24.9), proportional reporting ratio (proportional reporting ratio = 13.3, χ2 = 113.7), and empirical Bayes geometric mean (empirical Bayes geometric mean = 13.3, 95% CI = 7.9). The median time to SIADH onset was 22 (interquartile range 6–692) days after PPI administration. PPI-associated SIADH generally led to a 2.95% fatality rate and a 79.7% hospitalization rate. The highest hospitalization death rate occurred in esomeprazole (91.2%).

Conclusion

According to our findings, more attention should be paid to SIADH within the first several months after the administration of PPIs. For women older than 65 years, dexlansoprazole may reduce the incidence of PPI-associated SIADH. Nonetheless, larger epidemiological studies are suggested to verify this conclusion.
Literature
1.
go back to reference Dubey V, Han M, Kopec W, Solov'yov IA, et al. K+ binding and proton redistribution in the E2P state of the H+, K+-ATPase. Sci Rep. 2018;8(1):1–11. Dubey V, Han M, Kopec W, Solov'yov IA, et al. K+ binding and proton redistribution in the E2P state of the H+, K+-ATPase. Sci Rep. 2018;8(1):1–11.
2.
go back to reference Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.PubMedPubMedCentralCrossRef Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273–97.PubMedPubMedCentralCrossRef
3.
go back to reference Kim JS, Kim BW, Kim DH, et al. Guidelines for non-variceal upper gastrointestinal bleeding. Korean J Gastroenterol. 2020;75(6):322–32.PubMedCrossRef Kim JS, Kim BW, Kim DH, et al. Guidelines for non-variceal upper gastrointestinal bleeding. Korean J Gastroenterol. 2020;75(6):322–32.PubMedCrossRef
4.
5.
go back to reference Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Ther Adv Gastroenterol. 2018;11:1–11.CrossRef Halfdanarson OO, Pottegard A, Bjornsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Ther Adv Gastroenterol. 2018;11:1–11.CrossRef
6.
go back to reference Pottegard A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lodrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9(5):671–8.CrossRef Pottegard A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lodrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Ther Adv Gastroenterol. 2016;9(5):671–8.CrossRef
7.
go back to reference Yuan J, Zhang C, Sparks JA, et al. Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Aliment Pharmacol Ther. 2020;52(3):449–58.PubMedPubMedCentralCrossRef Yuan J, Zhang C, Sparks JA, et al. Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Aliment Pharmacol Ther. 2020;52(3):449–58.PubMedPubMedCentralCrossRef
8.
go back to reference Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci. 2019;20(20):5203.PubMedCentralCrossRef Fossmark R, Martinsen TC, Waldum HL. Adverse effects of proton pump inhibitors-evidence and plausibility. Int J Mol Sci. 2019;20(20):5203.PubMedCentralCrossRef
9.
go back to reference Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018;3(6):457–62.PubMedPubMedCentralCrossRef Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018;3(6):457–62.PubMedPubMedCentralCrossRef
10.
12.
go back to reference van der Zalm IJB, Tobe TJM, Logtenberg SJJ. Omeprazole-induced and pantoprazole-induced asymptomatic hyponatremia: a case report. J Med Case Rep. 2020;14(1):83.PubMedPubMedCentralCrossRef van der Zalm IJB, Tobe TJM, Logtenberg SJJ. Omeprazole-induced and pantoprazole-induced asymptomatic hyponatremia: a case report. J Med Case Rep. 2020;14(1):83.PubMedPubMedCentralCrossRef
13.
go back to reference Ferreira F, Mateus S, Santos AR, Moreira H, Ferreira NR. Pantoprazole-related symptomatic hyponatremia. Eur J Case Rep Intern Med. 2016;3(2):000341.PubMedPubMedCentral Ferreira F, Mateus S, Santos AR, Moreira H, Ferreira NR. Pantoprazole-related symptomatic hyponatremia. Eur J Case Rep Intern Med. 2016;3(2):000341.PubMedPubMedCentral
14.
go back to reference van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.PubMedCrossRef van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.PubMedCrossRef
16.
go back to reference Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf. 2010;19(11):1159–65.PubMedCrossRef Ooba N, Kubota K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol Drug Saf. 2010;19(11):1159–65.PubMedCrossRef
17.
go back to reference Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.PubMedCrossRef Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.PubMedCrossRef
18.
go back to reference Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393–7.PubMedCrossRef Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393–7.PubMedCrossRef
19.
go back to reference Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929–48.PubMedCrossRef Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929–48.PubMedCrossRef
20.
go back to reference Noren GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740–57.PubMedCrossRef Noren GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Stat Med. 2006;25(21):3740–57.PubMedCrossRef
21.
go back to reference Hauben M. A brief primer on automated signal detection. Ann Pharmacother. 2003;37(7–8):1117–23.PubMedCrossRef Hauben M. A brief primer on automated signal detection. Ann Pharmacother. 2003;37(7–8):1117–23.PubMedCrossRef
22.
go back to reference Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25(6):381–92.PubMedCrossRef Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf. 2002;25(6):381–92.PubMedCrossRef
23.
go back to reference DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177–90. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53(3):177–90.
24.
go back to reference Martin J, Burnier M, Lu H. Approach to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Rev Med Suisse. 2018;14(628):2116–20.PubMed Martin J, Burnier M, Lu H. Approach to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Rev Med Suisse. 2018;14(628):2116–20.PubMed
26.
go back to reference Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–42.PubMedCrossRef Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–42.PubMedCrossRef
27.
go back to reference Falhammar H, Lindh JD, Calissendorff J, Skov J, Nathanson D, Mannheimer B. Associations of proton pump inhibitors and hospitalization due to hyponatremia: a population-based case-control study. Eur J Intern Med. 2019;59:65–9.PubMedCrossRef Falhammar H, Lindh JD, Calissendorff J, Skov J, Nathanson D, Mannheimer B. Associations of proton pump inhibitors and hospitalization due to hyponatremia: a population-based case-control study. Eur J Intern Med. 2019;59:65–9.PubMedCrossRef
28.
go back to reference Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–53.PubMedCrossRef Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–53.PubMedCrossRef
29.
go back to reference Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65–72.PubMedCrossRef Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68(2):65–72.PubMedCrossRef
30.
go back to reference Engelen A, Christiaens P, Bossuyt P, et al. Syndrome of inappropriate antidiuretic hormone secretion caused by proton pump inhibitor use. Acta Gastroenterol Belg. 2018;81(4):542.PubMed Engelen A, Christiaens P, Bossuyt P, et al. Syndrome of inappropriate antidiuretic hormone secretion caused by proton pump inhibitor use. Acta Gastroenterol Belg. 2018;81(4):542.PubMed
31.
go back to reference Falhammar H, Skov J, Calissendorff J, et al. Associations between antihypertensive medications and severe hyponatremia: a Swedish population-based case-control study. J Clin Endocrinol Metab. 2020;105(10):dgaa194.PubMedCrossRef Falhammar H, Skov J, Calissendorff J, et al. Associations between antihypertensive medications and severe hyponatremia: a Swedish population-based case-control study. J Clin Endocrinol Metab. 2020;105(10):dgaa194.PubMedCrossRef
32.
go back to reference Cuesta M, Thompson CJ. The syndrome of inappropriate antidiuresis (SIAD). Best Pract Res Clin Endocrinol Metab. 2016;30(2):175–87.PubMedCrossRef Cuesta M, Thompson CJ. The syndrome of inappropriate antidiuresis (SIAD). Best Pract Res Clin Endocrinol Metab. 2016;30(2):175–87.PubMedCrossRef
33.
go back to reference Lin KJ, Garcia Rodriguez LA, Hernandez-Diaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf. 2011;20(7):718–28.PubMedCrossRef Lin KJ, Garcia Rodriguez LA, Hernandez-Diaz S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf. 2011;20(7):718–28.PubMedCrossRef
34.
go back to reference Quan S, Frolkis A, Milne K, et al. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. World J Gastroenterol. 2014;20(46):17568–77.PubMedPubMedCentralCrossRef Quan S, Frolkis A, Milne K, et al. Upper-gastrointestinal bleeding secondary to peptic ulcer disease: incidence and outcomes. World J Gastroenterol. 2014;20(46):17568–77.PubMedPubMedCentralCrossRef
35.
go back to reference Chen TS, Chang FY. The prevalence and risk factors of reflux esophagitis among adult Chinese population in Taiwan. J Clin Gastroenterol. 2007;41(9):819–22.PubMedCrossRef Chen TS, Chang FY. The prevalence and risk factors of reflux esophagitis among adult Chinese population in Taiwan. J Clin Gastroenterol. 2007;41(9):819–22.PubMedCrossRef
Metadata
Title
Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study
Authors
Mengmeng Wang
Lingjian Zhang
Min Jia
Junyan Wang
Zhiwen Shen
Shuyue Wang
Xinghui Zhang
Jing Xu
Zheng Zheng
Xuanrui Lv
Xiaoyu Zong
Hui Li
Jin Zhou
Tong Meng
Mingzhu Chen
Bin Zhao
Jian Gong
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02818-3

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.